If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
162
results.
Updated on
01/09/2024 [06:58:00]
Absstract of: CN118557544A
本发明涉及一种高渗透纳米载药体系的通用合成方法与应用，属于生物医药技术领域。具体的说，利用疏水性药物介导聚乙二醇‑15‑羟基硬脂酸酯(HS)共组装获得具有组织穿透性的纳米载药体系，其不仅能快速穿过细胞膜进入细胞，还能在细胞间快速传递，并在脂肪，肿瘤组织中展现出高的渗透作用。本发明不仅能实现多种疏水性药物的共组装加载，还能实现肿瘤，肥胖等多种疾病的协同治疗应用。
Absstract of: CN118557741A
聚合前药、仿生纳米聚合前药、其制备方法及应用，属于生物学工程领域。本申请制备方法制备得到的仿生纳米聚合前药，通过具有细胞膜成分的膜包被纳米前药，尤其是使用细胞外囊泡膜，通过中性粒细胞外囊泡的“伪装”减少机体免疫系统的清除，延长体内循环时间；并在中性粒细胞外囊泡特异性识别CIRI部位作用下跨BBB高效聚集到CIRI病变部位，继而响应高ROS微环境释放PB药物，实现清除ROS、抗炎以及保护神经元细胞的功能，从而最终达到安全、高效治疗CIRI的目的。
Absstract of: CN118562832A
本发明属于核酸疫苗技术领域，具体涉及一种编码HTNV包膜糖蛋白GP的基因、其编码的表达载体、mRNA分子及其用途。该基因的核苷酸序列SEQ ID NO.1所示。将该基因插入pVAX1载体中构建pVAX1‑GPHTNV。将pVAX1‑GPHTNV封装在LNP中，构成LNP‑GPDNA疫苗。在该基因上增加了UTR及聚腺苷酸尾后，将其插入pGEM‑UTR载体构建pGEM‑UTR‑GPHTNV，再通过体外转录及加帽修饰得到mRNA分子，构成GPmRNA疫苗。动物实验证实，三种疫苗均能够有效诱导抗汉坦病毒特异性细胞和体液免疫应答，具有良好的体内攻毒保护效果、体外中和活性以及应用安全性。
Absstract of: AU2022395910A1
Provided herein are methods and compositions for alteration of protein expression that can result in cell differentiation or production of proteins of biopharmaceutical relevance or engineered cells for use as therapeutic medicinal products. The compositions may comprise a saccharide, a nucleic acid molecule, and/or a polymeric material. The compositions and methods may promote or facilitate uptake of a nucleic acid by a cell. The compositions and methods may promote or facilitate differentiation of the cell.
Absstract of: AU2022376283A1
The present disclosure is directed to methods of using albumin as an emulsifier to assist in blending otherwise immiscible components. Methods use albumin as an emulsifier and a carrier. The disclosure also teaches utilization of albumin as a microencapsulating liquid, gel or powder and as a drug or nutraceutical carrier wherein bioavailability is increased.
Absstract of: CN118557548A
本发明公开了一种可靶向根除耐药幽门螺杆菌（H.pylori）的多功能纳米酶的制备方法和应用，属于纳米技术领域。该纳米酶（FPB‑Co‑Ch）由包覆了Co3O4纳米粒子的新型普鲁士蓝类似物再修饰壳聚糖制备得到。通过对该制剂的多酶活性进行测定，得到该复合纳米粒子具有pH选择性的氧化酶（OXD）、过氧化物酶（POD）、过氧化氢酶（CAT）及超氧化物歧化酶（SOD）活性；这些多酶活性促使该纳米酶能够在胃酸环境（pH 1.3）中持续产生大量O2以及·OH，从而抑制对氧气敏感的H.pylori的生长。通过H.pylori的体外清除实验，发现该复合纳米酶在胃酸环境（pH 1.3）的抑菌效果良好；通过模拟胃环境耐受性实验，发现该复合纳米酶在胃液中具有很好的稳定性；通过动物实验，发现该纳米酶抗菌活性明显优于其他对照组纳米材料，其能够特异性作用于胃内酸性环境，能够有效预防并根除H.pylori感染导致的疾病。同时，该纳米酶可通过分解H2O2及·O2‑清除ROS，来缓解由于感染H.pylori引起的胃黏膜炎症反应。
Absstract of: CN118561969A
本发明属于mRNA疫苗制备技术领域，具体涉及一种通过优化全长结构蛋白序列设计的基孔肯雅病毒广谱性mRNA疫苗，具体的，本发明提供一种多核苷酸，所述多核苷酸序列如SEQ ID NO.2所示，所述mRNA疫苗中含SEQ ID NO.2所示序列转录获得的mRNA，本发明提供的疫苗具有更强烈的细胞免疫应答水平，剂量达到一定水平后产生的结合抗体水平更高维持的更加持久，并且中和抗体水平也具有一定作用，在广谱性上，疫苗对来自西非谱系、印度洋谱系与东中南非谱系的假病毒产生中和抗体，具有交叉保护性。
Absstract of: WO2023084217A1
The disclosure provides a sub-micron particle comprising a first payload molecule, a lipid structure and a plurality of amphiphilic polymer chains surrounding the lipid structure. The first payload molecule is a macromolecule, optionally a nucleic acid. Additionally, the hydrophobicity of the amphiphilic polymer chains changes in response to an external stimulus.
Absstract of: CN118557547A
本发明提供了膜包被的自组装的纳米药物颗粒、中间体、其制备方法及应用，本申请提供方法制备得到的治疗动脉粥样硬化(AS)的纳米药物颗粒。首先通过自组装单元，尤其是具有两亲性的中药单体成分包裹治疗AS的活性药物成分，形成均匀的纳米药物颗粒；然后再通过细胞膜包被技术将前述颗粒包被在细胞膜内部；细胞膜上具有炎症内皮细胞特异性识别的蛋白分子，可以特异性靶向AS病变部位，通过细胞膜的靶向作用将纳米药物颗粒精准递送到AS病灶部位；同时由于细胞膜上具有细胞免疫识别分子，可以实现免疫逃逸，避免免疫排斥反应；同样避免被清除，提高药物的有效及安全性。
Absstract of: CN118557723A
本发明提供一种响应肿瘤微环境激活且自增效的自发光光动力纳米粒子及其制备方法和应用。本发明提供的纳米粒子是一种空间稳定混合胶束，由二硬脂酰磷脂酰乙醇胺‑聚乙二醇2000分子和二油酰基卵磷脂包载鲁米诺‑四苯基卟啉化合物和油酸稳定的过氧化钙纳米粒子制成，该纳米粒子可响应肿瘤微环境的弱酸性pH释放过氧化氢和氧气并通过鲁米诺‑四苯基卟啉化合物介导的化学发光共振能量转移产生活性氧，达到响应肿瘤激活、缓解肿瘤乏氧、基于增效肿瘤原位自发光光动力抑制肿瘤生长和转移的目的。
Absstract of: CN118557546A
本发明公开了一种覆载绿原酸的人血清白蛋白‑硒纳米颗粒的制备方法，包括如下步骤：S1、以绿原酸、人血清白蛋白为原料，通过偶联反应制备覆载绿原酸的人血清白蛋白；S2、以步骤S1制备的覆载绿原酸的人血清白蛋白为分散剂制备覆载绿原酸的人血清白蛋白‑硒纳米颗粒。本发明一种覆载绿原酸的人血清白蛋白‑硒纳米颗粒的制备方法，利用人血清白蛋白与药物小分子绿原酸进行偶联后，将其作为分散剂稳定纳米硒，不仅可以防止纳米硒聚集，提高其稳定性，还可以高效递送药物小分子绿原酸，提高其水溶性与生物利用度；更重要的是，还可使纳米硒与药物小分子绿原酸协同发挥疗效功能。
Absstract of: CN118557545A
本发明涉及一种自噬抑制剂协同电动力疗法的纳米材料，涉及新材料领域。该纳米材料包括自噬抑制剂和载体，载体为铂铱纳米颗粒，自噬抑制剂与载体中铂的质量比为1：(7‑13)。利用该纳米材料，通过调控免疫微环境以及实现增强的电动力治疗共同发挥对肿瘤的长期抑制作用，实现对大体积肿瘤的有效治疗，为电动力疗法进行协同治疗提供新策略。
Absstract of: CN118562831A
本发明提供了一种核酸药物及其制备方法与应用。所述核酸药物的核苷酸序列为SEQ ID NO:2‑5中的一种或几种。所述核酸药物具有高的T细胞应答能力和诱导gE特异性记忆B细胞生成能力，为水痘‑带状疱疹的预防和治疗提供了新的途径，降低了罹患带状疱疹及其并发症引的风险。
Absstract of: CN118571409A
本发明公开了一种磁驱微纳米机器人异构集群基于pH映射递送药物的方法，属于微纳米机器人技术领域。本发明构建了由传感微纳米机器人和载药微纳米机器人组成的异构集群，在磁场操控下，两种微纳米机器人可以形成微纳米机器人异构集群，并在未知环境中主动巡航。同时，集群中的传感微纳米机器人可以利用其pH响应结构色对周围环境进行实时pH映射，并在遭遇酸性靶标时产生结构色变化，映射/绘制局部pH值分布图，从而报告靶标的存在和位置；利用此pH映射结果作为视觉反馈，可以引导异构集群在外部交变磁场操控下运动到达并覆盖检测到的靶标，从而将载药微纳机器人精准递送到靶标区域。
Absstract of: WO2024177490A1
The present invention pertains to: an albumin nanocomposite comprising a phytochemical; and a composition, containing same, for improving muscle disease. More specifically, the present invention pertains to an albumin nanocomposite comprising a phytochemical that exhibits the effects of suppressing muscle loss caused by oxidative stress or inflammatory responses and promoting the differentiation of myoblasts into muscle cells. The albumin nanocomposite comprising a phytochemical effectively delivers the phytochemical by targeting immune cells that induce active oxygen and inflammatory responses, thereby suppressing muscle cell atrophy and promoting differentiation by regulating muscle loss signaling mechanisms induced by active oxygen and inflammatory responses, and thus can improve muscle loss and prevent and treat muscular dystrophy. Therefore, the composition containing the albumin nanocomposite comprising a phytochemical according to the present invention may be provided as a composition for improving muscle disease.
Absstract of: US2024287015A1
Provided herein is a method for producing an ionizable lipid that comprises: (i) reacting fatty esters in a Claisen condensation reaction in the presence of a catalyst, the Claisen condensation employing a weak base and carried out at a temperature of between −10 and 60 degrees Celsius to produce a ketoester; (ii) reacting the ketoester produced in step (i) under conditions to produce a ketone from the ketoester in one or more steps via a hydrolysis and decarboxylation of the ketoester; and (iii) preparing the ionizable lipid from the ketone thereof using one or more synthesis steps resulting in an addition of an ionizable head group moiety to (a) the ketone; or (b) an alcohol produced from an optional reduction of the ketone to produce the alcohol, thereby producing the ionizable lipid. The ionizable lipid produced in step (iii) may be formulated in a drug delivery vehicle.
Absstract of: WO2024177923A1
Described herein is a composition for immunization of a mammal against an infection by a parasite. The composition includes an extracellular vesicle produced by a red blood cell infected with the parasite; and a pharmaceutically acceptable carrier for parenteral administration. Also described herein is a method for immunizing a subject against an infection by a parasite. The method includes administering to the subject an effective amount of an extracellular vesicle exuded by the parasite, which resides with the host red blood cell.
Absstract of: WO2024177424A1
The present invention relates to a novel ionizable lipid containing a biodegradable bond. Specifically, the ionizable lipid containing a biodegradable ester and/or amide bond according to the present invention stably delivers an anionic drug when prepared into lipid nanoparticles, and exhibits an excellent effect, in particular, in delivering nucleic acids, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.
Absstract of: WO2024177426A1
The present invention relates to a novel ionizable lipid containing a biodegradable bond for in vivo drug delivery. Specifically, the ionizable lipid containing a biodegradable ester or amide bond, of the present invention, stably delivers an anionic drug when prepared into lipid nanoparticles, and exhibits an excellent effect, in particular, during nucleic acid delivery, and thus can be effectively used in related technical fields such as that of lipid nanoparticle-mediated gene therapy.
Absstract of: WO2024174883A1
A nanoformulation carrying trabectedin and paclitaxel. A pH-sensitive amphiphilic biodegradable material (such as PCL-PEOz) is used for respectively wrapping paclitaxel and trabectedin to form a stable micelle, so as to improve the bioavailability of drugs, reduce the critical concentration of the micelle, and realize long-acting circulation in vivo. Different targeting groups are linked to the surface of the micelle so as to respectively and efficiently target tumor cells and tumor macrophages, are introduced into the cells by means of receptor mediation, and release drugs by means of self-degradation, thereby achieving antibody and chemical drug combined targeted treatment on malignant tumors having high expression of a certain antibody/antigen. It is found according to a PDOX model that the combination therapy of a formulation of trabectedin and paclitaxel can achieve a better tumor inhibition effect than an equivalent amount of separate paclitaxel or trabectedin, and achieve lower toxicity.
Absstract of: WO2024174882A1
A nanomicelle loaded with a hydrophobic anti-cancer drug lithospermum oxime, and a preparation method for the nanomicelle. A pH sensitive amphiphilic biodegradable material PCL-PEOz and the like are used to form a micelle with a drug by means of self-assembly to improve the water solubility of the drug, improve the bioavailability, and achieve in-vivo long-acting circulation. The micelle releases the drug by means of degradation of the micelle. Moreover, cetuximab and the like can be linked to the surface of the micelle to treat colon cancer and the like, and the effect of targeting tumor cells is improved by means of receptor-mediated endocytosis and the like.
Absstract of: WO2024174011A1
This invention relates to liposomes having mucus-penetrating action and rates of incorporation of a retinoid, for example retinoic acid (RA), greater than those obtained in solid lipid nanoparticles (0.1%), thus increasing the uptake thereof via the nasal mucosa, and to the method for preparing a liposome. The present invention also relates to an intranasal composition, for example a vaccine, comprising said liposome, which is more effective than existing vaccines, the method for preparing same and the use thereof for preventing illnesses.
Absstract of: AU2023231101A1
A nucleic acid-lipid nanoparticle is provided, which comprises: a nucleic acid molecule and a lipid mixture. The lipid mixture comprises: an ionizable amino lipid present in an amount of 20 mol % to 60 mol %; a phospholipid present in an amount of 5 mol % to 20 mol %; cholesterol present in an amount of 25 mol % to 60 mol %; and a PEGylated lipid present in an amount of 0.2 mol % to 6 mol %. In addition, methods using the aforesaid nucleic acid-lipid nanoparticle are also provided.
Absstract of: US2024285728A1
Methods for preventing neural tube defects in embryos of diabetic females via administration of Survivin-containing exosomes derived from Flk-1+ mesoderm progenitor cells are reported.
Nº publicación: US2024285793A1 29/08/2024
Applicant:
CASE WESTERN RESERVE UNIV [US]
CASE WESTERN RESERVE UNIVERSITY
Absstract of: US2024285793A1
A method of treating cancer in a subject that includes administering to the cancer a therapeutically effective amount of an anti-cancer virus particle, the virus particle including a rod-shaped plant virus or virus-like particle and mitoxantrone (MTO) or analogs thereof, wherein the MTO is loaded into the interior channel of the rod-shaped plant virus particle.
BOPI
Electronic site
